Latest News & Features
Biotechnology
MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body. 30 January 2024
Medtech
Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties. 30 January 2024
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival. 25 January 2024
Biotechnology
Despite the clamour for guidance, applicants, attorneys, and lawyers may be in for a frustrating wait before the UK updates AI protections, says Rebecca Lawrence of DLA Piper. 25 January 2024
Big Pharma
Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing. 25 January 2024
Big Pharma
Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031. 23 January 2024
Americas
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA. 23 January 2024
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners. 23 January 2024
Biotechnology
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. 18 January 2024
Biotechnology
Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal. 18 January 2024